FDA records identify Menicon Co, Ltd. as the applicant behind Miru 1day UpSide (midafilcon A), cleared as K262495 with a decision date of September 17, 2026. The filing describes a soft contact lens for daily wear, classified in the ophthalmic advisory committee and regulated under 21 CFR 886.5925. A separate FDA letter for K193399, dated June 17, 2020, addresses the same trade and device name to Menicon Co., Ltd. at an Aoi, Naka-ku, Nagoya address, and lists product codes LPL and MVN. The manufacturer's own professional and consumer pages describe the product as a daily replacement lens. [1][6][9]

The 2026 clearance record

The K262495 entry in FDA's 510(k) database lists Menicon Co, Ltd. as applicant, with a device name of Miru 1day UpSide (midafilcon A) and product code LPL. The record shows a Traditional clearance type, a decision code of SESE with the description Substantially Equivalent, and a summary statement. The date received is July 20, 2026, and the decision date is September 17, 2026. The same record places the applicant's filing address in Nagoya, Japan, and names the ophthalmic advisory committee. [1]

The supplied collection for this company holds one linked record, a 510(k) with a decision of SESE, and the smaller record sample likewise contains that single entry. These counts describe the filings gathered as of the snapshot date and are not a measure of total company portfolio, sales or safety performance. [1]

Earlier filing for the same device name

An FDA letter dated June 17, 2020 responds to Menicon Co., Ltd. regarding K193399, naming Miru 1day UpSide (midafilcon A) as the trade and device name. The letter cites 21 CFR 886.5925, the soft (hydrophilic) contact lens regulation, a Class II designation, and product codes LPL and MVN. It is addressed to the company's international regulatory affairs contact at an Aoi, Naka-ku, Nagoya address. [6]

The letter's stated scope covers daily wear, single use only, for optical correction of refractive ametropia in aphakic and non-aphakic people with disease-free eyes and a stated limit on refractive astigmatism. That scope belongs to the 2020 correspondence and is not restated as the scope of the 2026 clearance. [6]

Product documentation from the manufacturer

Menicon's professional site lists Miru 1day UpSide among its disposable lenses and offers region-specific content, directing United States visitors to a separate Menicon America site. The manufacturer's instruction-for-use page for the product provides downloadable documents by country, including Australia, the United Kingdom and the United States. [4][8]

The consumer page for the product, published by Menicon America, lists a daily replacement wear schedule, package options of 30 and 90 lenses, and a lens marking. It also references company data on file, including a 2021 daily contact lens clinical study and 2017 patient experience surveys. Those references are the manufacturer's own statements; the underlying study results are not part of the FDA records reviewed here. [9]

Applicant identity and limits of the record

Across the FDA records, the legal applicant is Menicon Co, Ltd., and the documented product is Miru 1day UpSide (midafilcon A). The Nagoya address appears as a filing and correspondence address in FDA documents and is not treated here as a verified corporate headquarters. No parent, subsidiary or brand relationship is confirmed by these sources beyond the manufacturer's regional web properties. [1][6]

Details not stated in the records, such as ownership structure, commercial availability in specific markets, and clinical performance, remain unknown. The clearance decisions establish regulatory status only and do not indicate efficacy or safety outcomes. [1][6]